Samsung Healthcare Weekly Summary
Core Content
This document provides an overview of the global and Korean healthcare sector, including indices, stock performances, price-to-earnings (P/E) ratios, price-to-book (P/B) ratios, and market share data. It is prepared by Samsung Securities analysts and is based on data from QuantiWise, Bloomberg, and DataStream. The report is intended to offer insights into the performance of various segments within the healthcare industry.
Key Information
Global Healthcare Indices
| Country |
Index |
Forward P/E (x) |
Portion of market cap (%) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
| Korea |
KRX Health Care |
33.0 |
4.9 |
0.7 |
1.6 |
4.6 |
(1.1) |
| Korea |
Kospi Medical Supplies |
43.5 |
2.3 |
0.2 |
1.0 |
9.0 |
6.7 |
| Korea |
Kosdaq Pharmaceuticals |
26.4 |
2.1 |
0.8 |
2.1 |
1.9 |
(3.8) |
| Korea |
Kosdaq Medical and Precision Machines |
15.7 |
0.5 |
(0.1) |
1.9 |
(0.9) |
(3.4) |
| US |
S&P 500 Healthcare |
16.4 |
8.4 |
0.6 |
2.1 |
6.4 |
10.1 |
| US |
S&P 500 Pharma/Biotech |
15.7 |
5.1 |
0.4 |
1.0 |
5.2 |
7.7 |
| US |
Nasdaq Biotechnology |
46.5 |
2.4 |
(0.6) |
1.9 |
4.9 |
11.7 |
| US |
S&P 500 Healthcare equipment and services |
17.7 |
3.3 |
0.9 |
3.7 |
8.2 |
14.1 |
| Europe |
MSCI Europe Healthcare |
16.9 |
11.5 |
1.6 |
3.8 |
8.6 |
9.5 |
| Europe |
MSCI Europe Pharm/Bio |
16.3 |
10.0 |
1.6 |
3.4 |
8.3 |
9.5 |
| Europe |
MSCI Europe Healthcare Equipment and Services |
23.2 |
1.5 |
2.0 |
6.9 |
10.4 |
9.9 |
| Japan |
MSCI Japan Healthcare |
23.4 |
7.3 |
0.5 |
1.0 |
2.8 |
1.3 |
| Japan |
MSCI Japan Pharm/Bio |
23.1 |
5.3 |
(0.5) |
0.2 |
1.6 |
0.4 |
| Japan |
Topix Pharma |
22.8 |
4.8 |
(0.0) |
0.5 |
2.1 |
0.9 |
| Japan |
MSCI Japan Healthcare Equipment and Services |
24.0 |
2.0 |
2.3 |
3.0 |
5.7 |
3.5 |
| China |
MSCI China Healthcare |
18.9 |
1.6 |
(1.2) |
(0.4) |
3.4 |
13.8 |
| India |
MSCI India Healthcare |
19.5 |
7.0 |
(1.5) |
(2.6) |
(5.6) |
(2.5) |
Korean Healthcare Sector
- Portion of trading volume: Healthcare accounts for 6.8% of total trading volume, a slight decrease of 0.1% from the previous month.
- Weekly share performance:
- Top 30: Positive performance with increases.
- Bottom 30: Negative performance with decreases.
Major Korean Healthcare Firms
Pharmaceutical Holdings
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Hanmi Science |
3,780 |
60,700 |
449.3 |
n/a |
5.4 |
n/a |
0.3 |
1.9 |
10.1 |
6.0 |
(30.2) |
| Green Cross Holdings |
1,598 |
32,700 |
25.0 |
n/a |
1.4 |
n/a |
(0.2) |
12.2 |
50.0 |
37.4 |
(0.9) |
| Donga Socio Holdings |
890 |
145,000 |
5.5 |
14.1 |
1.1 |
1.0 |
(0.3) |
3.9 |
14.6 |
(7.4) |
(11.0) |
| Daewoong |
748 |
64,300 |
25.8 |
62.8 |
0.8 |
n/a |
0.0 |
13.6 |
44.7 |
46.0 |
0.0 |
| JW Holdings |
486 |
7,890 |
n/a |
n/a |
0.6 |
n/a |
(2.3) |
(5.5) |
13.2 |
(2.6) |
(5.5) |
| Chongkundang Holdings |
336 |
67,100 |
11.1 |
n/a |
0.9 |
n/a |
(2.3) |
(5.5) |
6.0 |
(11.0) |
(15.7) |
Pharmaceuticals
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Hanmi Pharm |
3,533 |
316,500 |
136.7 |
90.3 |
4.8 |
5.1 |
5.7 |
4.6 |
15.5 |
10.8 |
(21.5) |
| Yuhan |
2,768 |
234,000 |
14.7 |
19.2 |
1.4 |
1.6 |
(1.1) |
0.7 |
25.8 |
17.3 |
(2.7) |
| Green Cross |
1,940 |
166,000 |
29.1 |
32.1 |
1.8 |
1.8 |
0.9 |
1.5 |
16.5 |
5.7 |
0.0 |
| SK Chemicals |
1,592 |
62,500 |
22.0 |
13.7 |
1.0 |
0.9 |
(2.3) |
(5.7) |
4.5 |
(6.7) |
(8.2) |
| Young Jin Pharm |
1,586 |
8,670 |
372.8 |
n/a |
14.8 |
n/a |
2.0 |
1.9 |
24.6 |
(1.7) |
(14.2) |
| Chong Kun Dang |
1,110 |
118,000 |
24.0 |
23.4 |
2.8 |
2.8 |
0.9 |
1.7 |
16.8 |
12.9 |
0.0 |
| Daewoong Pharm |
1,062 |
91,700 |
29.5 |
26.1 |
1.4 |
1.8 |
(0.1) |
4.2 |
20.8 |
33.5 |
(2.3) |
| Bukwang Pharmaceutical |
943 |
21,150 |
74.4 |
n/a |
2.7 |
1.6 |
1.4 |
(2.3) |
(3.4) |
(19.9) |
(31.8) |
| JW Pharmaceutical |
832 |
43,200 |
n/a |
114.3 |
4.0 |
3.4 |
(0.5) |
(6.0) |
(1.3) |
(18.0) |
(21.7) |
| Donga ST |
802 |
95,000 |
83.3 |
70.6 |
1.5 |
1.4 |
(1.0) |
(1.1) |
7.3 |
(10.0) |
(12.0) |
| Samjin Pharm |
476 |
34,250 |
16.0 |
13.8 |
2.6 |
2.2 |
9.8 |
(1.4) |
(5.5) |
(15.6) |
(15.6) |
| Kwang Dong Pharm |
460 |
8,770 |
15.9 |
n/a |
0.9 |
n/a |
(0.3) |
(3.0) |
7.9 |
2.9 |
(4.7) |
| Boryung Pharm |
434 |
49,100 |
97.6 |
6.6 |
2.7 |
1.6 |
(1.0) |
(4.8) |
(5.2) |
(15.6) |
(22.9) |
| Daewon Pharmaceutical |
415 |
22,800 |
17.1 |
14.9 |
2.1 |
2.2 |
1.1 |
4.1 |
13.9 |
19.7 |
(0.9) |
| Korea United Pharm |
321 |
19,800 |
15.4 |
13.3 |
1.5 |
1.5 |
(3.4) |
(1.1) |
7.0 |
(3.6) |
(12.0) |
| Huons |
321 |
51,900 |
25.6 |
12.5 |
4.2 |
2.7 |
(5.1) |
(3.9) |
(4.1) |
(18.7) |
(20.9) |
| Whan In Pharm |
315 |
16,950 |
18.0 |
16.1 |
1.1 |
1.1 |
(2.3) |
(6.0) |
(1.4) |
(14.2) |
(15.6) |
APIs
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Kolon Life Science |
1,073 |
141,000 |
67.5 |
n/a |
3.4 |
n/a |
(0.8) |
9.3 |
30.6 |
20.1 |
(8.1) |
| ST Pharm |
860 |
46,550 |
12.0 |
15.0 |
2.7 |
2.3 |
2.2 |
(1.0) |
(3.5) |
(6.0) |
(13.8) |
| Kyongbo Pharmaceutical |
308 |
12,900 |
26.3 |
18.9 |
2.6 |
2.2 |
(3.4) |
(1.9) |
0.0 |
(7.5) |
(11.0) |
| Daebongs |
144 |
13,000 |
15.7 |
13.2 |
2.1 |
n/a |
0.0 |
11.6 |
10.6 |
9.7 |
0.0 |
| Estech Pharma |
127 |
10,800 |
29.2 |
n/a |
1.6 |
n/a |
1.4 |
2.9 |
21.6 |
(1.7) |
(14.2) |
| CKD Bio |
118 |
22,600 |
13.1 |
n/a |
0.9 |
n/a |
(0.9) |
(3.8) |
7.1 |
(4.0) |
(6.2) |
| Hwail Pharm |
103 |
7,130 |
18.3 |
n/a |
1.1 |
n/a |
(1.7) |
(1.9) |
(3.5) |
(12.1) |
(14.6) |
Industrial-Use Enzymes
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Amicogen |
415 |
45,500 |
255.6 |
n/a |
5.0 |
n/a |
(0.1) |
6.1 |
11.0 |
2.1 |
(14.3) |
| GenoFocus |
163 |
18,150 |
111.5 |
n/a |
3.4 |
n/a |
(1.4) |
(4.7) |
7.7 |
(6.7) |
(13.6) |
Biosimilars
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Samsung Biologics |
11,910 |
180,000 |
n/a |
n/a |
2.5 |
3.0 |
(0.8) |
1.4 |
4.1 |
(11.2) |
(16.1) |
| Samsung Biologics |
11,031 |
90,100 |
73.8 |
37.6 |
6.4 |
4.7 |
(1.1) |
(0.2) |
(11.2) |
(16.7) |
(15.6) |
Stem Cell Therapy
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Chabiotech |
655 |
12,950 |
38.0 |
20.5 |
2.2 |
1.8 |
1.2 |
(3.0) |
8.4 |
(11.2) |
(14.8) |
| Medipost |
481 |
61,200 |
n/a |
n/a |
2.9 |
n/a |
1.5 |
(0.6) |
17.2 |
(12.7) |
(15.1) |
| Pharmicell |
258 |
4,420 |
n/a |
n/a |
3.2 |
n/a |
0.8 |
(6.3) |
(7.4) |
(14.8) |
(18.1) |
| Tego Science |
186 |
50,200 |
243.7 |
n/a |
7.2 |
n/a |
1.4 |
2.9 |
21.6 |
(1.4) |
(15.0) |
| Anterogen |
149 |
19,950 |
471.7 |
194.5 |
2.4 |
1.6 |
(0.2) |
(1.9) |
(3.5) |
(12.1) |
(14.7) |
| Corestem |
146 |
9,270 |
n/a |
n/a |
2.7 |
n/a |
(7.0) |
(13.8) |
(10.0) |
(20.4) |
(23.1) |
Immune Cell Therapy
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Green Cross Cell |
344 |
29,400 |
n/a |
286.6 |
8.1 |
8.6 |
0.3 |
(1.0) |
(2.0) |
(5.1) |
(10.0) |
| JW Shinyak |
311 |
7,970 |
n/a |
n/a |
3.6 |
n/a |
2.1 |
(2.6) |
(13.8) |
(22.4) |
(28.5) |
| Green Cross Lab Cell |
275 |
26,100 |
102.9 |
n/a |
5.5 |
n/a |
(1.9) |
(0.4) |
(5.5) |
(16.1) |
(17.0) |
Molecular Diagnostics
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Seegene |
950 |
36,200 |
128.7 |
89.0 |
6.4 |
6.2 |
0.3 |
(0.2) |
(1.2) |
(3.0) |
(7.7) |
| Panagene |
191 |
5,970 |
n/a |
n/a |
9.6 |
n/a |
(1.0) |
(0.3) |
(7.3) |
(12.5) |
(19.3) |
| MG MED |
91 |
38,550 |
n/a |
n/a |
3.7 |
n/a |
0.4 |
(4.3) |
(4.8) |
(17.2) |
(27.5) |
| Bioneer |
90 |
5,600 |
n/a |
n/a |
4.6 |
n/a |
7.1 |
11.1 |
(19.8) |
(24.0) |
(33.7) |
New Drug Development
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| ViroMed |
1,473 |
92,300 |
2818.8 |
n/a |
7.5 |
n/a |
1.5 |
0.3 |
(2.0) |
(3.0) |
(11.4) |
| Genexine |
729 |
40,850 |
n/a |
n/a |
4.9 |
5.1 |
(0.6) |
(3.7) |
7.9 |
(5.3) |
(11.5) |
| Sillajen |
726 |
11,350 |
n/a |
n/a |
4.0 |
n/a |
0.0 |
(5.8) |
11.3 |
(14.3) |
(17.5) |
| HLB |
505 |
14,050 |
n/a |
n/a |
5.3 |
n/a |
(0.4) |
(9.4) |
4.1 |
(10.8) |
(20.4) |
| GemVax & Kael |
404 |
13,200 |
n/a |
n/a |
8.3 |
n/a |
1.5 |
(6.1) |
(9.3) |
(10.8) |
(19.8) |
| Crystal Genomics |
399 |
15,400 |
n/a |
n/a |
5.3 |
n/a |
1.3 |
(1.0) |
(3.6) |
(11.1) |
(12.1) |
| Intron Biotechnology |
369 |
24,550 |
n/a |
n/a |
9.6 |
n/a |
0.2 |
(2.2) |
(4.4) |
(1.5) |
(3.7) |
| Legochem Biosciences |
283 |
28,400 |
n/a |
n/a |
3.7 |
n/a |
(3.4) |
(1.4) |
(7.5) |
(19.9) |
(26.2) |
| Access Bio |
136 |
5,040 |
n/a |
n/a |
n/a |
n/a |
(2.3) |
0.2 |
(8.0) |
(17.7) |
(19.6) |
Medical Devices
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Osstem Implant |
774 |
54,200 |
36.9 |
25.0 |
8.1 |
5.4 |
1.5 |
(1.0) |
(8.0) |
(10.7) |
(15.7) |
| Viewworks |
667 |
66,700 |
22.2 |
19.8 |
5.4 |
4.7 |
1.4 |
(4.3) |
(6.5) |
(11.5) |
(16.3) |
| Dio |
546 |
36,000 |
30.3 |
24.4 |
5.4 |
4.0 |
(1.2) |
(3.3) |
(5.9) |
(2.1) |
(13.9) |
| Value Added Technology |
449 |
30,250 |
21.7 |
7.2 |
3.7 |
2.1 |
(2.0) |
(1.0) |
(1.2) |
(3.4) |
(16.5) |
| Dentium |
436 |
39,350 |
n/a |
17.5 |
n/a |
3.7 |
(3.3) |
(7.6) |
(4.4) |
(8.6) |
(16.5) |
| Interjo |
426 |
39,500 |
21.2 |
17.8 |
4.5 |
3.7 |
(0.3) |
(5.1) |
(4.2) |
(1.5) |
(6.2) |
| InBody |
400 |
29,200 |
21.8 |
19.4 |
4.0 |
3.5 |
(3.8) |
(1.9) |
(5.5) |
(2.8) |
(14.8) |
| Lutronic |
355 |
14,200 |
68.7 |
65.8 |
3.3 |
2.5 |
(3.1) |
(0.4) |
(1.5) |
(1.5) |
(1.2) |
| Rayence |
321 |
19,350 |
18.1 |
17.4 |
1.7 |
1.7 |
(2.0) |
(1.0) |
(3.4) |
(4.6) |
(10.0) |
| JVM |
279 |
44,050 |
24.5 |
15.9 |
2.3 |
2.0 |
(1.3) |
(2.1) |
(4.4) |
(10.4) |
(11.4) |
| Sewoon Medical |
173 |
3,960 |
22.7 |
15.2 |
2.6 |
n/a |
(3.3) |
(7.6) |
(4.2) |
(10.8) |
(16.5) |
| Hans Biomed |
169 |
17,150 |
37.0 |
24.3 |
3.5 |
3.1 |
(7.0) |
(0.4) |
(0.5) |
(2.2) |
(10.0) |
| Huvitz |
153 |
12,850 |
14.6 |
12.6 |
2.7 |
n/a |
(3.4) |
(0.3) |
(0.8) |
(12.7) |
(15.6) |
| Corentec |
138 |
14,050 |
114.8 |
n/a |
2.3 |
n/a |
2.2 |
(0.3) |
(0.8) |
(1.7) |
(1.7) |
| Mediana |
111 |
12,850 |
17.8 |
12.4 |
3.2 |
2.2 |
(0.8) |
(1.9) |
(5.5) |
(12.1) |
(19.3) |
Telemedicine
| Company |
Market Cap (KRWb) |
Share Price (KRW) |
P/E (2016) |
P/E (2017E) |
P/B (2016) |
P/B (2017E) |
1-w (%) |
1-m (%) |
3-m (%) |
ytd (%) |
From Peak (%) |
| Infinit Healthcare |
178 |
7,290 |
23.6 |
n/a |
2.4 |
n/a |
2.1 |
(2.0) |
(3.4) |
(2.3) |
(2.1) |
| UBCare |
146 |
3,625 |
27.9 |
n/a |
3.9 |
n/a |
(1.0) |
(5.9) |
(1.2) |
(3.7) |
(4.3) |
| BIT Computer |
101 |
6,050 |
16.9 |
n/a |
2.7 |
n/a |
(1.3) |
(2.6) |
(1.5) |
(2.4) |
(1. |